After managing a patient with impaired kidney function on a second-generation antipsychotic (SGA), we thought it would be helpful to have a tool to streamline the process of determining the appropriate renal dose adjustment for SGAs and selecting an SGA for a patient with compromised renal function.
Renal Dose Adjustments – A Brief Overview
Renal dose adjustments play a pivotal role in medication management. Some medications rely on the kidneys for elimination from the body. When kidney function is decreased, these medications are not cleared from the body as quickly, leading to potential accumulation and an increased risk of side effects.
Which SGAs Require Renal Dose Adjustments?
Among the SGAs, five medications require renal dose adjustments:
brexpiprazole, lurasidone, paliperidone, risperidone, and cariprazine.
For some of these medications, the recommended dose adjustments may vary depending on the dosage form. Of note, olanzapine/samidorphan is not recommended when the estimated glomerular filtration rate (eGFR) is less than 15 mL/minute/1.73 m2. However, this renal dose adjustment is based on the samidorphan component, as olanzapine does not require renal dose adjustments. Ideally, these medications would be avoided in patients with renal impairment; however, there are cases where these medications are necessary or better suited for the patient. In a real-world scenario, my patient with renal dysfunction responded well to their current antipsychotic, so we opted not to risk a relapse by changing the medication.
The table below outlines the recommendations for SGAs requiring renal dose adjustments.
Enter your patient's creatinine clearance (CrCl), and the table will show relevant dose adjustments based on your patient's renal function.
| Drug | CrCl (mL/min) | Dose Adjustments |
|---|---|---|
| Brexpiprazole | <60 | Maximum dose: Agitation associated with dementia due to Alzheimer disease: 2 mg once daily Major depressive disorder: 2 mg once daily Schizophrenia: 3 mg once daily |
| Cariprazine | <30 | Use not recommended (has not been studied) |
| Lurasidone | <50 | Initial: 20 mg daily Maximum: 80 mg/day |
| Paliperidone ER Tablet | 50 to <80 | Initial: 3 mg daily; maximum: 6 mg daily |
| 10 to <50 | Initial: 1.5 mg daily; maximum: 3 mg daily | |
| <10 | Use not recommended | |
| Paliperidone (Invega Sustenna) |
50 to <80 | Initiation: 156 mg IM on day 1, then 117 mg IM after 7 days Maintenance: 78 mg IM 5 weeks after initiation dose Subsequent Maintenance Dose Maximum: 156 mg IM monthly |
| <50 | Use not recommended | |
| Paliperidone (Invega Trinza) |
50 to <80 | Maintenance dose based on Sustenna dose Maximum dose: 546 mg IM every 3 months |
| <50 | Use not recommended | |
| Paliperidone (Invega Hafyera) |
<90 | Use not recommended |
| Risperidone Tablet | 30 to 60 | Do not exceed 75% of typical dose for specific indication |
| 10 to <30 | Do not exceed 50% of typical dose for specific indication | |
| <10 | Consider alternative agent Initial: 25% of typical dose of specific indication Titrate by 0.5 mg at the recommended frequency for the specific indication |
|
| Risperidone IM (Risperdal Consta) |
10 to ≤60 | Use with caution Initial: 12.5-25 mg IM every 2 weeks Titrate by 12.5 mg no sooner than every 4 weeks |
| <10 | Avoid Use, if possible Initial: 12.5-25 mg IM every 2 weeks Maximum dose: 25 mg IM every 2 weeks |
|
| Risperidone SubQ (Perseris) |
10 to ≤60 | Use with caution (has not been studied) |
| <10 | Avoid Use | |
| Risperidone SubQ (Uzedy) |
10 to ≤60 | Use with caution (has not been studied) |
| <10 | Avoid Use |
References: